Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Next-Generation Gas Chromatograph and GC/MSD Enable New Levels of Performance

By BiotechDaily International staff writers
Posted on 12 Feb 2013
Image: The new Agilent 5977A Series GC/MSD, including the new 7890B GC (adjacent at right) (Photo courtesy of Agilent).
Image: The new Agilent 5977A Series GC/MSD, including the new 7890B GC (adjacent at right) (Photo courtesy of Agilent).
A new gas chromatograph (GC) and a mass selective detector to function with the GC offer a broad, feature-rich portfolio, and enable superior levels of sensitivity, reliability, and productivity.

Agilent Technologies (Santa Clara, CA, USA) introduces the Agilent 7890B gas chromatograph and the 5977A Series GC/MSD (mass selective detector) to offer the industry's broadest, feature-rich portfolio of superior performance GC, GC/MSD, and related software. Agilent also offers factory-tested, preconfigured solutions to help fast-track setup and operation. "Customers will find significant product improvements, eco-friendly capabilities, and lower cost of ownership, along with unsurpassed performance,” said Monty Benefiel, Agilent vice president for Gas Phase Systems.

Based on the known reliability of the Agilent GC platform, the new 7890B GC is faster, easier to operate, and more cost-effective. The 7890B GC features Improved performance specifications with advances in numerous detector modules; Lower operating costs and ecofriendly operation with power/gas management and sleep/wake modes; Seamless ordering of consumables and parts with an interactive graphical Parts Finder tool and consumables database; Easier, faster method development with integrated GC calculators and wizards; Better asset and resource management with integrated maintenance tools; Improved recovery of active compounds with Agilent's exclusive end-to-end Inert Flow Path deactivation technology; Reduced downtime for MS maintenance using the new Fast Vent feature.

The Agilent 7890B GC runs on Agilent OpenLAB Chromatography Data System software. The new Agilent OpenLAB CDS is up to 40 times faster than previous versions, with a new Data Analysis package and Intelligent Reporting. Advanced interactive integration tools and graphical displays accelerate data review, reducing time-to-results and freeing up operators for other tasks. "Our customers require the means to efficiently and accurately analyze their data as well as information about their laboratory assets to support decision making or gain further scientific insight. OpenLAB does all of that," said Bruce von Herrmann, Agilent vice president for Software and Informatics. "With streamlined workflows and complete data and method migration from ChemStation and EZChrom, OpenLAB is a fully scalable solution for a single laboratory, multiple workgroups, and entire enterprises."

The Agilent 5977A Series GC/MSD provides all the benefits of the 7890B GC plus features a redesigned inert MS ion source that enhances performance with highly efficient ion collection. The 5977A Series GC/MSD now offers the highest sensitivity on the market, with a new specification metric, the Instrument Detection Limit, for system-level performance in practice. Using Agilent's TwisTorr 304 FS turbomolecular vacuum pump, optimized for light gas operation, the new 5977A GC/MSD system is efficient and rugged, and has been evaluated and certified to meet Agilent’s leading quality standards. The GC/MSD runs on Agilent MassHunter Workstation software solution for high-throughput MS data analysis, and also includes a full version of MSD ChemStation to ensure compatibility with previously purchased instruments.

Related Links:
Agilent Technologies, Inc.
Agilent 7890B GC and 5977A Series GC/MSD
Agilent Inert Flow Path Solutions



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.